ABL-specific tyrosine kinase inhibitor imatinib as salvage therapy in a child with Philadelphia chromosome-positive acute mixed lineage leukemia (AMLL).
Selle
B
B
Bär
C
C
Hecker
S
S
Schmidt-Rohr
U
U
Viehmann
S
S
Debatin
K-M
KM
Reinhardt
D
D
D000208:Acute Disease; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001549:Benzamides; D019070:Cell Lineage; D002648:Child; D004791:Enzyme Inhibitors / Q000008:administration & dosage*; D016044:Fusion Proteins, bcr-abl / Q000037:antagonists & inhibitors / Q000235:genetics; D006801:Humans; D000068877:Imatinib Mesylate; D007938:Leukemia / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D008297:Male; D010677:Philadelphia Chromosome; D010879:Piperazines / Q000008:administration & dosage*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011743:Pyrimidines / Q000008:administration & dosage*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D016879:Salvage Therapy
D000970:Antineoplastic Agents; D001549:Benzamides; D004791:Enzyme Inhibitors; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases; D016044:Fusion Proteins, bcr-abl